RxDoctor Payments Data

Jeffrey Jordan, MD

Ophthalmology · Bangor, MENPI 1861480246

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $208 of the $325 with a category attached, or 63.9%. 6 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 54.4% of the total. Reporting peaked in 2024 at $123 and has fallen 55.8% since, to $54 in 2025. That places this record below the midpoint for ophthalmology clinicians in ME, where the typical reported total is $371.

$325in general payments, 2019–2025

Across 10 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$177
  • Optovue, Inc.$45
  • AbbVie$35
  • Oyster Point Pharma, Inc.$30
  • Aerie Pharmaceuticals, Inc.$20
  • Carl Zeiss Meditec, Inc.$17

What the payments were for

  • Food & beverage$20864%
  • Education$10031%
  • Gifts$175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 45th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$127,896
Medicare patients
512
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate50$29,934
LumiganBimatoprost65$29,769
Travoprost78$11,286
Timolol Maleate219$9,276
Latanoprost503$7,058
Brinzolamide36$6,244
Prednisolone Acetate75$3,086
Dorzolamide Hcl133$2,481
Brimonidine Tartrate275$2,428
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat89$1,162
ValacyclovirValacyclovir Hcl18$888
Ketorolac Tromethamine19$658
MoxifloxacinMoxifloxacin Hcl28$539
ErythromycinErythromycin Base19$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$20$29,93450 claims
AbbVieLumigan$35$29,76965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →